Dopamine agonists and neuroprotection in Parkinson's disease
Identifieur interne : 001F05 ( Main/Corpus ); précédent : 001F04; suivant : 001F06Dopamine agonists and neuroprotection in Parkinson's disease
Auteurs : A. H. V. SchapiraSource :
- European Journal of Neurology [ 1351-5101 ] ; 2002-11.
English descriptors
Abstract
Dopamine agonists are effective in reversing the motor symptoms of Parkinson's disease (PD). They have also shown that they can delay or prevent the onset of motor complications associated with levodopa use. Recent attention has focused on the possible role for dopamine agonists in neuroprotection. Numerous studies have demonstrated that a variety of dopamine agonists can protect dopaminergic neuronal function in several toxin model systems. Pramipexole in particular has shown efficacy in reducing toxicity to MPTP, MPP, rotenone and 6‐hydroxydopamine. Recent studies in early PD using imaging parameters as a surrogate marker of dopaminergic neuronal integrity have shown that pramipexole and ropinirole can apparently retard the rate of cell loss. These observations are of considerable interest, but additional studies are required to confirm a neuroprotective function for these dopamine agonists.
Url:
DOI: 10.1046/j.1468-1331.9.s3.9.x
Links to Exploration step
ISTEX:5EBB5FF195E929150136AE9CFCBE977E8E614E10Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Dopamine agonists and neuroprotection in Parkinson's disease</title><author><name sortKey="Schapira, A H V" sort="Schapira, A H V" uniqKey="Schapira A" first="A. H. V." last="Schapira">A. H. V. Schapira</name><affiliation><mods:affiliation>University Department of Clinical Neurosciences, Royal Free and University College, Medical School, Rowland Hill Street, London, NW3 2PF, and Institute of Neurology, UCL, Queen Square, London, WC1N 3BG</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:5EBB5FF195E929150136AE9CFCBE977E8E614E10</idno><date when="2002" year="2002">2002</date><idno type="doi">10.1046/j.1468-1331.9.s3.9.x</idno><idno type="url">https://api.istex.fr/document/5EBB5FF195E929150136AE9CFCBE977E8E614E10/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001F05</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Dopamine agonists and neuroprotection in Parkinson's disease</title><author><name sortKey="Schapira, A H V" sort="Schapira, A H V" uniqKey="Schapira A" first="A. H. V." last="Schapira">A. H. V. Schapira</name><affiliation><mods:affiliation>University Department of Clinical Neurosciences, Royal Free and University College, Medical School, Rowland Hill Street, London, NW3 2PF, and Institute of Neurology, UCL, Queen Square, London, WC1N 3BG</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">European Journal of Neurology</title><idno type="ISSN">1351-5101</idno><idno type="eISSN">1468-1331</idno><imprint><publisher>Blackwell Science, Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2002-11">2002-11</date><biblScope unit="volume">9</biblScope><biblScope unit="supplement">s3</biblScope><biblScope unit="page" from="7">7</biblScope><biblScope unit="page" to="14">14</biblScope></imprint><idno type="ISSN">1351-5101</idno></series><idno type="istex">5EBB5FF195E929150136AE9CFCBE977E8E614E10</idno><idno type="DOI">10.1046/j.1468-1331.9.s3.9.x</idno><idno type="ArticleID">ENE0083</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1351-5101</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>aetiology</term><term>dopamine agonist</term><term>levodopa</term><term>neuroprotection</term><term>pathogenesis</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Dopamine agonists are effective in reversing the motor symptoms of Parkinson's disease (PD). They have also shown that they can delay or prevent the onset of motor complications associated with levodopa use. Recent attention has focused on the possible role for dopamine agonists in neuroprotection. Numerous studies have demonstrated that a variety of dopamine agonists can protect dopaminergic neuronal function in several toxin model systems. Pramipexole in particular has shown efficacy in reducing toxicity to MPTP, MPP, rotenone and 6‐hydroxydopamine. Recent studies in early PD using imaging parameters as a surrogate marker of dopaminergic neuronal integrity have shown that pramipexole and ropinirole can apparently retard the rate of cell loss. These observations are of considerable interest, but additional studies are required to confirm a neuroprotective function for these dopamine agonists.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>A. H. V. Schapira</name><affiliations><json:string>University Department of Clinical Neurosciences, Royal Free and University College, Medical School, Rowland Hill Street, London, NW3 2PF, and Institute of Neurology, UCL, Queen Square, London, WC1N 3BG</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>aetiology</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>dopamine agonist</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>levodopa</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>neuroprotection</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>pathogenesis</value></json:item></subject><articleId><json:string>ENE0083</json:string></articleId><language><json:string>eng</json:string></language><abstract>Dopamine agonists are effective in reversing the motor symptoms of Parkinson's disease (PD). They have also shown that they can delay or prevent the onset of motor complications associated with levodopa use. Recent attention has focused on the possible role for dopamine agonists in neuroprotection. Numerous studies have demonstrated that a variety of dopamine agonists can protect dopaminergic neuronal function in several toxin model systems. Pramipexole in particular has shown efficacy in reducing toxicity to MPTP, MPP, rotenone and 6‐hydroxydopamine. Recent studies in early PD using imaging parameters as a surrogate marker of dopaminergic neuronal integrity have shown that pramipexole and ropinirole can apparently retard the rate of cell loss. These observations are of considerable interest, but additional studies are required to confirm a neuroprotective function for these dopamine agonists.</abstract><qualityIndicators><score>6.56</score><pdfVersion>1.3</pdfVersion><pdfPageSize>638 x 822 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>6</keywordCount><abstractCharCount>906</abstractCharCount><pdfWordCount>5752</pdfWordCount><pdfCharCount>37032</pdfCharCount><pdfPageCount>8</pdfPageCount><abstractWordCount>130</abstractWordCount></qualityIndicators><title>Dopamine agonists and neuroprotection in Parkinson's disease</title><genre><json:string>article</json:string></genre><host><volume>9</volume><publisherId><json:string>ENE</json:string></publisherId><pages><total>8</total><last>14</last><first>7</first></pages><issn><json:string>1351-5101</json:string></issn><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1468-1331</json:string></eissn><title>European Journal of Neurology</title><doi><json:string>10.1111/(ISSN)1468-1331</json:string></doi></host><publicationDate>2002</publicationDate><copyrightDate>2002</copyrightDate><doi><json:string>10.1046/j.1468-1331.9.s3.9.x</json:string></doi><id>5EBB5FF195E929150136AE9CFCBE977E8E614E10</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/5EBB5FF195E929150136AE9CFCBE977E8E614E10/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/5EBB5FF195E929150136AE9CFCBE977E8E614E10/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/5EBB5FF195E929150136AE9CFCBE977E8E614E10/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Dopamine agonists and neuroprotection in Parkinson's disease</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Blackwell Science, Ltd</publisher><pubPlace>Oxford, UK</pubPlace><availability><p>WILEY</p></availability><date>2002</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Dopamine agonists and neuroprotection in Parkinson's disease</title><author><persName><forename type="first">A. H. V.</forename><surname>Schapira</surname></persName><affiliation>University Department of Clinical Neurosciences, Royal Free and University College, Medical School, Rowland Hill Street, London, NW3 2PF, and Institute of Neurology, UCL, Queen Square, London, WC1N 3BG</affiliation></author></analytic><monogr><title level="j">European Journal of Neurology</title><idno type="pISSN">1351-5101</idno><idno type="eISSN">1468-1331</idno><idno type="DOI">10.1111/(ISSN)1468-1331</idno><imprint><publisher>Blackwell Science, Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2002-11"></date><biblScope unit="volume">9</biblScope><biblScope unit="supplement">s3</biblScope><biblScope unit="page" from="7">7</biblScope><biblScope unit="page" to="14">14</biblScope></imprint></monogr><idno type="istex">5EBB5FF195E929150136AE9CFCBE977E8E614E10</idno><idno type="DOI">10.1046/j.1468-1331.9.s3.9.x</idno><idno type="ArticleID">ENE0083</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2002</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Dopamine agonists are effective in reversing the motor symptoms of Parkinson's disease (PD). They have also shown that they can delay or prevent the onset of motor complications associated with levodopa use. Recent attention has focused on the possible role for dopamine agonists in neuroprotection. Numerous studies have demonstrated that a variety of dopamine agonists can protect dopaminergic neuronal function in several toxin model systems. Pramipexole in particular has shown efficacy in reducing toxicity to MPTP, MPP, rotenone and 6‐hydroxydopamine. Recent studies in early PD using imaging parameters as a surrogate marker of dopaminergic neuronal integrity have shown that pramipexole and ropinirole can apparently retard the rate of cell loss. These observations are of considerable interest, but additional studies are required to confirm a neuroprotective function for these dopamine agonists.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>aetiology</term></item><item><term>dopamine agonist</term></item><item><term>levodopa</term></item><item><term>neuroprotection</term></item><item><term>Parkinson's disease</term></item><item><term>pathogenesis</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2002-11">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/5EBB5FF195E929150136AE9CFCBE977E8E614E10/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell Science, Ltd</publisherName><publisherLoc>Oxford, UK</publisherLoc></publisherInfo><doi origin="wiley" registered="yes">10.1111/(ISSN)1468-1331</doi><issn type="print">1351-5101</issn><issn type="electronic">1468-1331</issn><idGroup><id type="product" value="ENE"></id><id type="publisherDivision" value="ST"></id></idGroup><titleGroup><title type="main" sort="EUROPEAN JOURNAL OF NEUROLOGY">European Journal of Neurology</title></titleGroup></publicationMeta><publicationMeta level="part" position="11000"><doi origin="wiley">10.1111/ene.2002.9.issue-s3</doi><numberingGroup><numbering type="journalVolume" number="9">9</numbering><numbering type="supplement">s3</numbering></numberingGroup><coverDate startDate="2002-11">November 2002</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="0000700" status="forIssue"><doi origin="wiley">10.1046/j.1468-1331.9.s3.9.x</doi><idGroup><id type="unit" value="ENE0083"></id></idGroup><countGroup><count type="pageTotal" number="8"></count></countGroup><titleGroup><title type="tocHeading1">Contents</title></titleGroup><eventGroup><event type="firstOnline" date="2002-12-11"></event><event type="publishedOnlineFinalForm" date="2002-12-11"></event><event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:2.3.2 mode:FullText source:FullText result:FullText" date="2010-03-06"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-01-24"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-16"></event></eventGroup><numberingGroup><numbering type="pageFirst" number="7">7</numbering><numbering type="pageLast" number="14">14</numbering></numberingGroup><correspondenceTo> Professor A. H. V. Schapira, University College Medical School, UCL, Rowland Hill Street, London NW3 2PF, UK (e‐mail: <email>schapira@rfc.ucl.ac.uk</email>).</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:ENE.ENE0083.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="0"></count><count type="formulaTotal" number="0"></count><count type="referenceTotal" number="74"></count><count type="wordTotal" number="6275"></count><count type="linksPubMed" number="0"></count><count type="linksCrossRef" number="0"></count></countGroup><titleGroup><title type="main">Dopamine agonists and neuroprotection in Parkinson's disease</title><title type="shortAuthors">A. H. V. Schapira</title><title type="short">Dopamine agonists and neuroprotection</title></titleGroup><creators><creator creatorRole="author" xml:id="cr1" affiliationRef="#a1"><personName><givenNames>A. H. V.</givenNames><familyName>Schapira</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="a1"><unparsedAffiliation>University Department of Clinical Neurosciences, Royal Free and University College, Medical School, Rowland Hill Street, London, NW3 2PF, and Institute of Neurology, UCL, Queen Square, London, WC1N 3BG</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en"><keyword xml:id="k1">aetiology</keyword><keyword xml:id="k2">dopamine agonist</keyword><keyword xml:id="k3">levodopa</keyword><keyword xml:id="k4">neuroprotection</keyword><keyword xml:id="k5">Parkinson's disease</keyword><keyword xml:id="k6">pathogenesis </keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><p>Dopamine agonists are effective in reversing the motor symptoms of Parkinson's disease (PD). They have also shown that they can delay or prevent the onset of motor complications associated with levodopa use. Recent attention has focused on the possible role for dopamine agonists in neuroprotection. Numerous studies have demonstrated that a variety of dopamine agonists can protect dopaminergic neuronal function in several toxin model systems. Pramipexole in particular has shown efficacy in reducing toxicity to MPTP, MPP, rotenone and 6‐hydroxydopamine. Recent studies in early PD using imaging parameters as a surrogate marker of dopaminergic neuronal integrity have shown that pramipexole and ropinirole can apparently retard the rate of cell loss. These observations are of considerable interest, but additional studies are required to confirm a neuroprotective function for these dopamine agonists.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Dopamine agonists and neuroprotection in Parkinson's disease</title></titleInfo><titleInfo type="abbreviated"><title>Dopamine agonists and neuroprotection</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Dopamine agonists and neuroprotection in Parkinson's disease</title></titleInfo><name type="personal"><namePart type="given">A. H. V.</namePart><namePart type="family">Schapira</namePart><affiliation>University Department of Clinical Neurosciences, Royal Free and University College, Medical School, Rowland Hill Street, London, NW3 2PF, and Institute of Neurology, UCL, Queen Square, London, WC1N 3BG</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Blackwell Science, Ltd</publisher><place><placeTerm type="text">Oxford, UK</placeTerm></place><dateIssued encoding="w3cdtf">2002-11</dateIssued><copyrightDate encoding="w3cdtf">2002</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="references">74</extent><extent unit="words">6275</extent></physicalDescription><abstract lang="en">Dopamine agonists are effective in reversing the motor symptoms of Parkinson's disease (PD). They have also shown that they can delay or prevent the onset of motor complications associated with levodopa use. Recent attention has focused on the possible role for dopamine agonists in neuroprotection. Numerous studies have demonstrated that a variety of dopamine agonists can protect dopaminergic neuronal function in several toxin model systems. Pramipexole in particular has shown efficacy in reducing toxicity to MPTP, MPP, rotenone and 6‐hydroxydopamine. Recent studies in early PD using imaging parameters as a surrogate marker of dopaminergic neuronal integrity have shown that pramipexole and ropinirole can apparently retard the rate of cell loss. These observations are of considerable interest, but additional studies are required to confirm a neuroprotective function for these dopamine agonists.</abstract><subject lang="en"><genre>Keywords</genre><topic>aetiology</topic><topic>dopamine agonist</topic><topic>levodopa</topic><topic>neuroprotection</topic><topic>Parkinson's disease</topic><topic>pathogenesis</topic></subject><relatedItem type="host"><titleInfo><title>European Journal of Neurology</title></titleInfo><genre type="Journal">journal</genre><identifier type="ISSN">1351-5101</identifier><identifier type="eISSN">1468-1331</identifier><identifier type="DOI">10.1111/(ISSN)1468-1331</identifier><identifier type="PublisherID">ENE</identifier><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><detail type="supplement"><caption>Suppl. no.</caption><number>s3</number></detail><extent unit="pages"><start>7</start><end>14</end><total>8</total></extent></part></relatedItem><identifier type="istex">5EBB5FF195E929150136AE9CFCBE977E8E614E10</identifier><identifier type="DOI">10.1046/j.1468-1331.9.s3.9.x</identifier><identifier type="ArticleID">ENE0083</identifier><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Blackwell Science, Ltd</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001F05 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001F05 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:5EBB5FF195E929150136AE9CFCBE977E8E614E10
|texte= Dopamine agonists and neuroprotection in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |